{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,9,23]],"date-time":"2026-09-23T06:52:55Z","timestamp":1790146375012,"version":"4.0.1"},"reference-count":21,"publisher":"Ovid Technologies (Wolters Kluwer Health)","issue":"8","content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":[],"published-print":{"date-parts":[[2009,4,27]]},"DOI":"10.1097\/tp.0b013e31819f1c49","type":"journal-article","created":{"date-parts":[[2009,5,21]],"date-time":"2009-05-21T17:08:42Z","timestamp":1242925722000},"page":"1240-1245","source":"Crossref","is-referenced-by-count":54,"title":["Preemptive Management of Epstein-Barr Virus Reactivation After Hematopoietic Stem-Cell Transplantation"],"prefix":"10.1097","volume":"87","author":[{"given":"Imran","family":"Ahmad","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Nguyen V.","family":"Cau","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"John","family":"Kwan","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Younes","family":"Maaroufi","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Nathalie","family":"Meuleman","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Mickael","family":"Aoun","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Philippe","family":"Lewalle","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Philippe","family":"Martiat","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Fran\u00e7oise","family":"Crokaert","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Dominique","family":"Bron","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"276","reference":[{"key":"R2-21-20210129","doi-asserted-by":"crossref","first-page":"155","DOI":"10.1016\/j.critrevonc.2005.03.015","article-title":"Post-transplant lymphoproliferative disorders (PTLD) after solid organ transplantation.","volume":"56","author":"Taylor","year":"2005","journal-title":"Crit Rev Oncol Hematol"},{"key":"R3-21-20210129","first-page":"377","article-title":"Risk factors for developing EBV-related B cell lymphoproliferative disorders (BLPD) after non-HLA-identical BMT in children.","volume":"18","author":"Gerritsen","year":"1996","journal-title":"Bone Marrow Transplant"},{"key":"R4-21-20210129","first-page":"264","article-title":"World Health Organization classification of tumours. Pathology and genetics of tumours of haematopoietic and lymphoid tissues.","author":"Harris","year":"2001"},{"key":"R5-21-20210129","first-page":"2208","article-title":"Risk of lymphoproliferative disorders after bone marrow transplantation: A multi-institutional study.","volume":"94","author":"Curtis","year":"1999","journal-title":"Blood"},{"key":"R6-21-20210129","doi-asserted-by":"crossref","first-page":"1661","DOI":"10.1002\/cncr.21391","article-title":"Rituximab therapy is effective for posttransplant lymphoproliferative disorders after solid organ transplantation: results of a phase II trial.","volume":"104","author":"Blaes","year":"2005","journal-title":"Cancer"},{"key":"R7-21-20210129","doi-asserted-by":"crossref","first-page":"1708","DOI":"10.1097\/01.tp.0000295987.12996.19","article-title":"Salvage therapy for relapsed posttransplant lymphoproliferative disorders (PTLD) with a second progression of PTLD after Upfront chemotherapy: The role of single-agent rituximab.","volume":"84","author":"Trappe","year":"2007","journal-title":"Transplantation"},{"key":"R8-21-20210129","doi-asserted-by":"crossref","first-page":"3053","DOI":"10.1182\/blood-2005-01-0377","article-title":"Efficacy and safety of rituximab in B-cell post-transplantation lymphoproliferative disorders: Results of a prospective multicenter phase 2 study.","volume":"107","author":"Choquet","year":"2006","journal-title":"Blood"},{"key":"R9-21-20210129","doi-asserted-by":"crossref","first-page":"1549","DOI":"10.1182\/blood.V92.5.1549.417k32_1549_1555","article-title":"Infusion of cytotoxic T cells for the prevention and treatment of Epstein-Barr virus-induced lymphoma in allogeneic transplant recipients.","volume":"92","author":"Rooney","year":"1998","journal-title":"Blood"},{"key":"R10-21-20210129","doi-asserted-by":"crossref","first-page":"626","DOI":"10.1093\/rheumatology\/kel393","article-title":"Repeated B lymphocyte depletion with rituximab in rheumatoid arthritis over 7 yrs.","volume":"46","author":"Popa","year":"2007","journal-title":"Rheumatology (Oxford)"},{"key":"R11-21-20210129","doi-asserted-by":"crossref","first-page":"5","DOI":"10.1002\/art.23171","article-title":"The effects of rituximab on immunocompetency in patients with autoimmune disease.","volume":"58","author":"Looney","year":"2008","journal-title":"Arthritis Rheum"},{"key":"R12-21-20210129","doi-asserted-by":"crossref","first-page":"4364","DOI":"10.1182\/blood.V99.12.4364","article-title":"Prevention of Epstein-Barr virus-lymphoproliferative disease by molecular monitoring and preemptive rituximab in high-risk patients after allogeneic stem cell transplantation.","volume":"99","author":"van Esser","year":"2002","journal-title":"Blood"},{"key":"R13-21-20210129","doi-asserted-by":"crossref","first-page":"351","DOI":"10.1128\/JCM.40.2.351-358.2002","article-title":"Evaluation of use of Epstein-Barr viral load in patients after allogeneic stem cell transplantation to diagnose and monitor posttransplant lymphoproliferative disease.","volume":"40","author":"G\u00e4rtner","year":"2002","journal-title":"J Clin Microbiol"},{"key":"R14-21-20210129","doi-asserted-by":"crossref","first-page":"539","DOI":"10.1038\/sj.bmt.1705289","article-title":"Preemptive diagnosis and treatment of Epstein-Barr virus-associated post transplant lymphoproliferative disorder after hematopoietic stem cell transplant: An approach in development.","volume":"37","author":"Weinstock","year":"2006","journal-title":"Bone Marrow Transplant"},{"key":"R15-21-20210129","doi-asserted-by":"crossref","first-page":"441","DOI":"10.1002\/jmv.21096","article-title":"Monitoring of Epstein-Barr virus load after hematopoietic stem cell transplantation for early intervention in post-transplant lymphoproliferative disease.","volume":"80","author":"Meerbach","year":"2008","journal-title":"J Med Virol"},{"key":"R16-21-20210129","doi-asserted-by":"crossref","first-page":"132","DOI":"10.1128\/JCM.37.1.132-136.1999","article-title":"Quantitative analysis of Epstein-Barr virus load by using a real-time PCR assay.","volume":"37","author":"Kimura","year":"1999","journal-title":"J Clin Microbiol"},{"key":"R17-21-20210129","doi-asserted-by":"crossref","first-page":"972","DOI":"10.1182\/blood.V98.4.972","article-title":"Epstein-Barr virus (EBV) reactivation is a frequent event after allogeneic stem cell transplantation (SCT) and quantitatively predicts EBV-lymphoproliferative disease following T-cell\u2013depleted SCT.","volume":"98","author":"van Esser","year":"2001","journal-title":"Blood"},{"key":"R18-21-20210129","doi-asserted-by":"crossref","first-page":"1165","DOI":"10.1182\/blood.V97.5.1165","article-title":"Frequent monitoring of Epstein-Barr virus DNA load in unfractionated whole blood is essential for early detection of posttransplant lymphoproliferative disease in high-risk patients.","volume":"7","author":"Stevens","year":"2001","journal-title":"Blood"},{"key":"R19-21-20210129","doi-asserted-by":"crossref","first-page":"465","DOI":"10.1111\/j.1600-6143.2005.00759.x","article-title":"Immunocompetent T-cells with a memory-like phenotype are the dominant cell type following antibody-mediated T-cell depletion.","volume":"5","author":"Pearl","year":"2005","journal-title":"Am J Transplant"},{"key":"R20-21-20210129","doi-asserted-by":"crossref","first-page":"2619","DOI":"10.1111\/j.1600-6143.2007.01972.x","article-title":"Dissociation of depletional induction and posttransplant lymphoproliferative disease in kidney recipients treated with alemtuzumab.","volume":"7","author":"Kirk","year":"2007","journal-title":"Am J Transplant"},{"key":"R21-21-20210129","doi-asserted-by":"crossref","first-page":"2151","DOI":"10.1128\/JCM.02308-06","article-title":"Comparison of various blood compartments and reporting units for the detection and quantification of Epstein-Barr virus in peripheral blood.","volume":"45","author":"Hakim","year":"2007","journal-title":"J Clin Microbiol"},{"key":"R22-21-20210129","doi-asserted-by":"crossref","first-page":"3979","DOI":"10.1182\/blood-2003-12-4287","article-title":"Prompt versus preemptive intervention for EBV lymphoproliferative disease.","volume":"103","author":"Wagner","year":"2004","journal-title":"Blood"}],"container-title":["Transplantation"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/www.ovid.com\/00007890-200904270-00021","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2026,8,6]],"date-time":"2026-08-06T17:47:41Z","timestamp":1786038461000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.ovid.com\/00007890-200904270-00021"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2009,4,27]]},"references-count":21,"journal-issue":{"issue":"8","published-print":{"date-parts":[[2009]]}},"URL":"https:\/\/doi.org\/10.1097\/tp.0b013e31819f1c49","relation":{},"ISSN":["0041-1337"],"issn-type":[{"value":"0041-1337","type":"print"}],"subject":[],"published":{"date-parts":[[2009,4,27]]}}}